Non-Hodgkin lymphoma (NHL) encompasses a diverse group of malignancies arising from malignant proliferation of lymphocytes, each subtype characterized by unique epidemiological, etiological, and clinical features. Prognostication is essential for guiding treatment decisions and improving patient outcomes. Prognostic scores, including traditional and molecular systems, offe insights into survival prediction. The aim of the present study was to evaluate the applicability of traditional prognostic scores barsed on clinical markers and laboratory biomarkers in predicting the outcomes of patients with primary nodal NHL.